Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma
Abstract Background Medulloblastoma (MB) patients with MYC oncogene amplification or overexpression exhibit extremely poor prognoses and therapy resistance. However, MYC itself has been one of the most challenging targets for cancer treatment. Here, we identify a novel marinopyrrole natural derivati...
Main Authors: | Don W. Coulter, Yashpal S. Chhonker, Devendra Kumar, Varun Kesherwani, Wafaa N. Aldhafiri, Erin M. McIntyre, Gracey Alexander, Sutapa Ray, Shantaram S. Joshi, Rongshi Li, Daryl J. Murry, Nagendra K. Chaturvedi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13046-024-02944-w |
Similar Items
-
Targeting protein synthesis pathways in MYC-amplified medulloblastoma
by: Devendra Kumar, et al.
Published: (2025-01-01) -
AZIN1 level is increased in medulloblastoma and correlates with c-Myc activity and tumor phenotype
by: Julie Sesen, et al.
Published: (2025-02-01) -
Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment
by: Sutapa Ray, et al.
Published: (2021-12-01) -
MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice
by: Carolin Göbel, et al.
Published: (2023-11-01) -
Modulation of Stemness and Differentiation Regulators by Valproic Acid in Medulloblastoma Neurospheres
by: Natália Hogetop Freire, et al.
Published: (2025-01-01)